New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer

Share :
Published: 17 May 2012
Views: 4052
Rating:
Save
Prof Richard Finn - Universtity of California, Los Angeles, USA

Prof Finn talks to ecancer at at the IMProving care And Knowledge through Translational research (IMPAKT) meeting in Brussels, May 2012, about the results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for firstline treatment of ER+/HER2- advanced breast cancer.

The new compound has the potential to be a standard of care in this setting, if a phase 3 study is successful, and also has promise in the adjuvant setting.


Filming Supported by Amgen